TechConnect World 2016
National SBIR/STTR Conference National Innovation Summit & Showcase Nanotech 2016
Nanotech 2016
 

Cancer Nanotechnology

Cancer Nanotechnology

Symposium Co-Chairs

Mansoor M. AmijiMansoor M. Amiji
Distinguished Professor & Chair, Dept. of Pharmaceutical Sciences, Co-Director, Nanomedicine Education & Research Consortium
Northeastern University

Anil PatriAnil Patri
Director, NCTR/ORA NanoCore, National Center for Toxicological Research
U.S. Food and Drug Administration

Confirmed Invited Speakers

Ashutosh ChilkotiSolving Drug Delivery Problems by Genetically Engineered Nanoparticles
Ashutosh Chilkoti
Theo Pilkington Professor, Chair, Department of Biomedical Engineering, Duke University

Vladimir ZharovIn vivo photoacoustic blood nanotesting
Vladimir Zharov
Professor, Director of the Arkansas Nanomedicine Center, University of Arkansas for Medical Sciences (UAMS)

Piotr GrodzinskiTranslating Cancer Nanomedicines - from Academic Research to Clinical and Commercial Outcomes: NCI Alliance for Nanotechnology in Cancer
Piotr Grodzinski
Director, Office of Cancer Nanotechnology Research, National Cancer Institute


Symposium Sessions

Monday May 23

10:30Cancer Nanotechnology I
1:30Cancer Nanotechnology II

Tuesday May 24

Cancer Nanotechnology: Posters 4:00

Symposium Program

Monday May 23

10:30Cancer Nanotechnology IPotomac 3
Session chair: Anil Patri, U.S. Food & Drug Administration (bio)
10:30Solving Drug Delivery Problems by Genetically Engineered Nanoparticles (invited presentation)
A. Chilkoti, Duke University, US
10:55In vivo photoacoustic blood nanotesting (invited presentation)
V. Zharov, University of Arkansas for Medical Sciences, US
11:20Single Cell Cisplatin Measurement by ICP-MS
L. Amable, S. Smith, C. Stephan, PerkinElmer, CA
11:45Enzymatic Transformation of Phosphate Decorated Magnetic Nanoparticles for Selectively Sorting and Inhibiting Cancer Cells
X. Du, J. Zhou, B. Xu, Brandeis University, US
12:05A plasma electrochemistry reactor for the synthesis of radioactive gold nanoparticles
M.A. Fortin, M. Bouchard, M. Laprise-Pelletier, S. Turgeon, Université Laval, CA
12:25A Novel Method for Preparation of Radiotherapeutic Nanoseeds for Brachtherapy
S. Moeendarbari, R. Tekade, A. Mulgaonkar, P. Christensen, S. Ramezani, G. Hassan, R. Jiang, O.K. Oz, X. Sun, Y. Hao, University of Texas at Arlington, US
1:30Cancer Nanotechnology IIPotomac 3
Session chair: Mansoor Amiji, Northeastern University, Anil Patri, U.S. Food, Drug Administration
1:30Translating Cancer Nanomedicines - from Academic Research to Clinical and Commercial Outcomes: NCI Alliance for Nanotechnology in Cancer (invited presentation)
P. Grodzinski, National Cancer Institute, US
1:55The unique subtype specific cytotoxic activity of silver nanoparticles toward claudin-low breast cancer in vitro and in vivo
J. Swanner, I. Tenvooren, B.W. Bernish, C.D. Fahrenholtz, P.A. Vidi, R. Singh, Wake Forest School of Medicine, US
2:15Plasmonic Nanocages as Photothermal Transducers for Nanobubble Cancer Therapy
I.H. Karampelas, K. Liu, E.P. Furlani, University at Buffalo, SUNY, US
2:35Novel Dielectrophoretic Devices for Rapid Isolation and Detection of Cancer Related DNA, RNA & Exosome Biomarkers and Drug Delivery Nanoparticles
M.J. Heller, S. Ibsen, J. Wright, J. Lewis, University of California San Diego, US
2:55Microfluidic Device for Aptamer-based Cancer Cell Capture and Gene Mutation Detection
S.J. Reinholt, H.G. Craighead, Cornell University, US
3:15Development of a filamentous plant virus for chemo-immunotherapy delivery
K.L. Lee, N.F. Steinmetz, Case Western Reserve University, US
3:35Magnetostructural characterization of iron oxide nanoparticles for cancer hyperthermia applications
A. Sharma, F. Soetaert, S.K. Kandala, C.L. Dennis, R. Ivkov, Johns Hopkins University School of Medicine, US

Tuesday May 24

Cancer Nanotechnology: Posters 4:00Expo Hall D & E
Gold Nanoshells With Micellar Core for The Delivery of Hydrophobic Chemotherapeutic and Cancer Photothermal Therapy
S-Y Lee, M-J Shieh, National Taiwan University, TW
The development of multifunctional nanocomplexs for drug delivery in oral cancer therapy
J.S. Huang, F.Y. Cheng, C.H. Tsai, D.B. Shieh, National Cheng Kung University, TW
Effects of metal oxide nanoparticles on DNA damage signaling in human colorectal cancer cells
J.D. Barnett, A. Sharma, J. Stewart, F. Bunz, R. Ivkov, The Johns Hopkins University School of Medicine, US
Hollow gold nanoparticles as efficient in vivo radiosensitizing agents for radiation therapy of breast cancer
A. Mulgaonkar, S. Moeendarbari, G. Hassan, W. Mao, Y. Hao, X. Sun, University of Texas Southwestern Medical Center, US
Mechanical Characterisation of Cancer Cells in Blood Circulation
V.K. Katiyar, K.S. Basavarajappa, IIT Roorkee, India, IN
Numerical modeling of the effect of field configurations on the magnetic nanoparticle delivery
M.K. Ghantasala, P. Ikonomov, T. Rajh, A. David, Western Michigan University, US
Particle analysis system for characterizing the surface properties of indiviual nanoparticles
R. Hart, C. Ashcroft, T. Castner, X. Li, N. Alessi, J. Zhang, B. DiPaolo, B. Cordovez, C. Earhart, Optofluidics, US
Magnetic and structural study of lanthanide ferrites for nanoparticles
S. Matiz Cely, L.A. Castillo, J.C. Cardenas, A. Reiber, Universidad de los Andes, CO

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Topics & Application Areas

  • Cancer diagnostics
  • Cancer biomarkers
  • Nanoparticle platforms
  • Drug delivery
  • Therapeutic delivery
  • Modeling & simulation
  • Cancer immunotherapeutics
  • Innovations in clinical diagnosis and therapy
  • Other

Sponsor & Exhibitor Opportunities

To receive announcements and news, please join our mailing list.

Click here to add this event to your calendar.

Platinum Sponsors

Gold Sponsor
Silver Sponsor

Corporate Acceleration Partners

Supporting Partners

TechConnect World 2016

Jointly produced by